Fidelis Capital Partners LLC Sells 134 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Fidelis Capital Partners LLC cut its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 15.5% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 732 shares of the company’s stock after selling 134 shares during the period. Fidelis Capital Partners LLC’s holdings in IDEXX Laboratories were worth $303,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also made changes to their positions in the company. FSA Wealth Management LLC bought a new stake in shares of IDEXX Laboratories in the third quarter valued at about $25,000. Retirement Wealth Solutions LLC bought a new position in IDEXX Laboratories during the 4th quarter worth about $31,000. Ashton Thomas Securities LLC purchased a new position in IDEXX Laboratories during the 3rd quarter valued at about $37,000. Kestra Investment Management LLC bought a new stake in shares of IDEXX Laboratories in the 4th quarter valued at about $38,000. Finally, Crews Bank & Trust purchased a new stake in shares of IDEXX Laboratories in the 4th quarter worth approximately $41,000. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the stock. Morgan Stanley cut their price objective on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a report on Wednesday, January 29th. Bank of America boosted their price target on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 4th. Leerink Partnrs raised IDEXX Laboratories to a “strong-buy” rating in a research report on Monday, December 2nd. StockNews.com upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Thursday, February 27th. Finally, Leerink Partners began coverage on shares of IDEXX Laboratories in a research report on Monday, December 2nd. They set an “outperform” rating and a $500.00 price target for the company. Three analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $533.75.

Insiders Place Their Bets

In other IDEXX Laboratories news, Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the completion of the sale, the director now owns 3,061 shares of the company’s stock, valued at approximately $1,426,242.34. The trade was a 49.50 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP George Fennell sold 9,986 shares of the business’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the sale, the executive vice president now owns 8,176 shares in the company, valued at approximately $3,781,645.28. The trade was a 54.98 % decrease in their position. The disclosure for this sale can be found here. 2.11% of the stock is owned by insiders.

IDEXX Laboratories Stock Performance

IDXX opened at $441.61 on Wednesday. The company has a market cap of $35.92 billion, a P/E ratio of 41.39, a price-to-earnings-growth ratio of 3.41 and a beta of 1.37. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. The firm’s 50-day moving average price is $436.35 and its 200-day moving average price is $450.43. IDEXX Laboratories, Inc. has a 52-week low of $398.50 and a 52-week high of $574.94.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.